Bharat Biotech is expected to submit the trial data of its intranasal vaccine against COVID-19 by the end of this year, people who know about the development told ET.

The trials, which include more than 600 participants, are being conducted with the participants divided into three groups. The first group is administered Covaxin as the initial dose followed by intranasal vaccine as the second dose. The second group is given both doses of intranasal vaccine, while the third group will get the intranasal vaccine as the initial dose and Covaxin as the second dose. The doses are given at an interval of 28 days. 

The adenoviral intranasal vaccine, BBV154, is a one of its kind COVID-19 vaccine. The Ministry of Science and Technology had stated earlier that phase-1 trial conducted in healthy individuals, aged 18 to 60 years, was well tolerated… (ET Healthworld, October 14, 2021)